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OUTCOMES RESEARCH
Inflammatory Biomarker Changes and Their Correlation
with Framingham Cardiovascular Risk and Lipid Changes
in Antiretroviral-Naive HIV-Infected Patients Treated
for 144 Weeks with Abacavir/Lamivudine/Atazanavir
with or without Ritonavir in ARIES
Benjamin Young,1,2 Kathleen E. Squires,3 Lisa L. Ross,4 Lizette Santiago,5 Louis M. Sloan,6
Henry H. Zhao,4 Brian C. Wine,4 Gary E. Pakes,4 David A. Margolis,4
and Mark S. Shaefer,7 for the ARIES (EPZ108859) Study Team
Abstract
Propensity for developing coronary heart disease (CHD) is linked with Framingham-defined cardiovascular risk
factors and elevated inflammatory biomarkers. Cardiovascular risk and inflammatory biomarkers were evalu-
ated in ARIES, a Phase IIIb/IV clinical trial in which 515 antiretroviral-naive HIV-infected subjects initially
received abacavir/lamivudine + atazanavir/ritonavir for 36 weeks. Subjects who were virologically suppressed
by week 30 were randomized 1:1 at week 36 to either maintain or discontinue ritonavir for an additional 108
weeks. Framingham 10-year CHD risk scores (FRS) and risk category of < 6% or ‡ 6%, lipoprotein-associated
phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP) were assessed
at baseline, week 84, and week 144. Biomarkers were stratified by FRS category. When ritonavir-boosted/
nonboosted treatment groups were combined, median hsCRP did not change significantly between baseline
(1.6mg/liter) and week 144 (1.4mg/liter) in subjects with FRS < 6% ( p = 0.535) or with FRS ‡ 6% (1.9mg/liter
vs. 2.0mg/liter, respectively; p = 0.102). Median IL-6 was similar for subjects with FRS < 6% ( p = 0.267) at
baseline (1.6 pg/ml) and week 144 (1.4 pg/ml) and for FRS ‡ 6% (2.0 pg/ml vs. 2.2 pg/ml, respectively;
p = 0.099). Median Lp-PLA2 decreased significantly ( p < 0.001) between baseline (197 nmol/min/ml) and week
144 (168 nmol/min/ml) in subjects with FRS < 6% and with FRS ‡ 6% (238 nmol/min/ml vs. 175 nmol/min/ml,
respectively; p < 0.001). In conclusion, in antiretroviral-naive subjects treated with abacavir-based therapy for 144
weeks, median inflammatory biomarker levels for hsCRP and IL-6 generally remained stable with no significant
difference between baseline and week 144 for subjects with either FRS < 6% or FRS ‡ 6%. Lp-PLA2 median
values declined significantly over 144 weeks for subjects in either FRS stratum.
Introduction
Clinical studies suggest that many factors may be as-sociated with an elevated risk of coronary heart disease
(CHD) amongHIV-infected comparedwith non-HIV-infected
individuals.1–3 Infection with HIV has been associated with
CHD-exacerbating chronic inflammation, as indicated by
elevated inflammatory biomarkers4 and hypercoagulability
leading to increased thrombogenesis.5,6 Due to the effective-
ness of highly active antiretroviral treatment (HAART), many
HIV-infected individuals are now living well beyond 50 years
of age and are also developing aging-related comorbid
medical conditions that may increase CHD risk, such as hy-
pertension, diabetes, impaired kidney function, and obesity.7
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A substantial proportion of these individuals have lifestyle
practices (e.g., smoking, sedentary, high-fat diet) that over
time can hasten atherosclerosis and thrombosis develop-
ment.7 HIV-infected patients have a higher prevalence of
prolonged corrected QT interval and an increased risk for
malignant arrhythmia and cardiovascular mortality.8 In ad-
dition, several non-age-related comorbid medical conditions
have the potential to negatively impact cardiac status (coin-
fection with hepatitis B or C, intravenous drug use, cocaine
use, excessive alcohol consumption). Finally, the combina-
tions of antiretroviral agents that comprise effective HAART
regimens may expose treated patients to long-term mito-
chondrial toxicity and drug-associated lipid elevation that
have an additive adverse impact on their heart and blood
vessels.9
As with HIV-negative individuals, thorough assessment of
cardiovascular risk in the HIV population requires focus
on traditional CHD risk factors strongly associated with
worsening cardiac status, as described in the Framingham
equation, and use of the readily available tool to calculate the
10-year risk of developing CHD [myocardial infarction (MI)
and coronary death] that incorporates patient age, gender,
total cholesterol, high-density lipoprotein (HDL)-cholesterol,
smoking status, systolic blood pressure, and antihypertensive
medication use.10,11 Clinical investigations have also evalu-
ated cardiovascular risk status by assessing the predictive
utility of measuring inflammation-associated biomarkers in
HIV-infected patients. In particular, changes in certain bio-
markers, including elevated levels of lipoprotein-associated
phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), and high-
sensitivity C-reactive protein (hsCRP), have each been asso-
ciated with increased cardiovascular risk.4,12
Dyslipidemic effects of antiretrovirals may potentially lead
to an increased risk in CHD in HIV-infected patients. While
atazanavir (ATV) has demonstrated little dyslipidemic impact
as compared with certain other protease inhibitors (PIs), there
are concerns regarding ritonavir (/r)-boosted PI regimens as
potentially increasing CHD risk, althoughwhether this would
be associated with any change in inflammatory biomarker
concentrations is unclear.13–16 Abacavir (ABC) is a generally
well-tolerated nucleoside reverse transcriptase inhibitor
(NRTI) that has been used in combination antiretroviral reg-
imens since the 1990s,17 and while the majority of studies18–22
have not demonstrated an increased ABC-attributable CHD
risk in the absence of confounding factors, two recent analyses
of observational cohorts23,24 reported a statistically increased
incidence inMI in HIV-infected patients receiving ABC-based
therapy with various third agents.
To better define any underlying cardiovascular risk
mechanism and to evaluate whether the use of ritonavir
boosting and/or ABC use could be affecting inflammatory
biomarker levels, a prospective cardiovascular risk analysis
was performed in ARIES (Atazanavir, Ritonavir, Induction
with Epzicom Study; EPZ108859). ARIES was a large phase
IIIb/IV treatment-simplification clinical trial in which anti-
retroviral therapy-naive subjects who achieved virologic
suppression byweek 30 on a regimen of abacavir/lamivudine
(ABC/3TC) plus atazanavir/ritonavir (ATV/r) were ran-
domized to remain on their original regimen or discontinue
the ritonavir component of the regimen for up to a total of 144
weeks.25–27 In this analysis, subjects had baseline assessment
of their Framingham 10-year CHD risk scores and were
classified as low or moderate risk groups ( < 6% or ‡ 6%).
Plasma concentrations of hsCRP, IL-6, and Lp-PLA2, and
fasting lipids were assessed at baseline, week 84, and week
144. These parameters were evaluated by treatment group
and/or by risk group to determine whether there were any
significant differences over time and if these changes were
influenced by baseline risk classification or long-term inclu-
sion of ritonavir in the HAART regimen.
Materials and Methods
Study design
ARIES was a randomized, open-label, noninferiority,
multicenter study and was conducted at outpatient HIV
clinics in the United States and Canada, and enrolled HLA-
B*5701-negative, antiretroviral-naive (£ 14 days of prior NRTI
and no prior PI or NNRTI) HIV-infected subjects ‡ 18 years
old with a screening viral load ‡ 1000 copies/ml and any
CD4 + cell level (a detailed study design has been presented
elsewhere25–27). Subjects with cardiovascular disease per se
could be included in this study, although subjects were
excluded if they had medical conditions that investigators
considered severe enough to compromise safety [diabetes
mellitus, congestive heart failure, cardiomyopathy, or other
cardiac dysfunction, clinically significant cardiac conduction
system disease, severe first-degree atrioventricular block (PR
interval > 0.26 s), or second- or third-degree atrioventricular
block].
The primary objective of ARIES was to evaluate the effi-
cacy, safety, tolerability, and durability of antiviral response
with ABC/3TC plus ATV/r compared to this regimen with-
out ritonavir. Subjects were initiated on a 36-week regimen of
once-daily ABC/3TC fixed-dose combination (600mg/
300mg, Epzicom, ViiV Healthcare, Research Triangle Park,
NC) plus ATV (300mg, Reyataz, Bristol-Myers Squibb, New
York, NY) and ritonavir (r) (100mg, Norvir, Abbott, Abbott
Park, IL). At week 36, subjects who had achieved a confirmed
viral load < 50 copies/ml by week 30 were randomized 1:1 to
either ABC/3TC plus unboosted ATV 400mg once daily (the
‘‘simplification’’ regimen) or to continue ABC/3TC plus
ATV/r 300/100mg once daily for 48 weeks. Subjects who
remained in the study through week 84 were offered the op-
portunity to participate in an ‘‘extension phase’’ of the study,
during which they were maintained on their current treat-
ment regimen through week 144. Subjects were not required
to have plasma HIV-1 RNA < 50 copies/ml at week 84 to
participate in the extension phase. Per protocol, subjects were
required to withdraw from the study if they failed to achieve
plasma HIV-1 RNA < 400 copies/ml by week 30 or if they
experienced confirmed HIV-1 RNA rebound ‡ 400 copies/ml
after achieving virologic suppression to < 400 copies/ml and
their confirmatory viral load result was ‡ 2,000 copies/ml. All
subjects provided written informed consent to participate in
the extension phase and the study was approved by the ethics
review board for each participating center. The study was
conducted in accordance with Good Clinical Practice.
Framingham risk measurement
Framingham 10-year CHD risk scores were calculated at
baseline, week 84, and week 144 using an algorithm that
factored in baseline cardiac risk factors including sex, age,
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total cholesterol, HDL-cholesterol, low-density lipoprotein
(LDL)-cholesterol, smoking status, blood pressure, and dia-
betes history.10,11 Subjects with Framingham 10-year CHD
risk scores < 6% (connoting low risk, i.e., < 6% chance of an
MI within the next 10 years) were subclassified from subjects
with risk scores ‡ 6% (connoting at least moderate risk, i.e.,
‡ 6% chance of an MI within the next 10 years).28
Biomarker measurements
EDTA-containing plasma samples were collected at base-
line, week 84, and week 144 for measurement of hsCRP and
IL-6 concentrations and Lp-PLA2 activity. All samples were
stored at –80C until analysis by Quest Diagnostic Nichols
Institute (San Juan Capistrano, CA). hsCRP concentrations
were assessed by fixed-time nephelometry using a Siemens
Dade Behring BN II nephelometer (Siemens Healthcare Di-
agnostics, Inc., Tarrytown, NY) with an intraassay coefficient
of variation (CV) of 3.7%, an interassay CV of 2.8%, and re-
portable range of 0.2–1,100 lg/ml. IL-6 concentrations were
assessed by enzyme-linked immunosorbent immunoassay
(ELISA) with an intraassay CV of 7.0%, interassay CV of
11.3%, and reportable range of 0.31–5.00 pg/ml. Lp-PLA2
activity was assessed by a colorimetric activity method using
a microtiter plate analyzer (CTL-US-Valencia). The assay
characteristics included intraassay precision of 1.7% and in-
terassay precision of 4.8%.
Lipid measurements
A fasting lipid panel was done at baseline and every 12
weeks thereafter through week 144. In the unboosted
ATV and ATV/r groups, median fasting lipid concentrations
were compared at baseline, week 84, and week 144. These
median concentrations were also compared to the cut-points
(maximum concentrations considered within normal limits)
established by the U.S. Department of Health and Human
Services National Cholesterol Education program (NCEP)
guidelines.29
Statistical analysis
All analyses of Framingham CHD risk scores, biomarkers,
and fasting lipids were done in the intent-to-treat-exposed
population. The biomarker values were grouped by the
Framingham CHD risk scores assessed at baseline for each
subject. Descriptive statistics were primarily used in pre-
senting the data, although a Wilcoxon signed rank test was
applied when comparing week 84 and week 144 Framing-
ham, biomarker, and lipid data with baseline values, while
Fisher’s exact test and Wilcoxon rank-sum test were em-
ployed for the between group comparisons. A p-value of less
than 0.05 was considered statistically significant.
Results
Patient characteristics and disposition
Five hundred and fifteen subjects were enrolled in ARIES,
and at week 36, 419 were randomized to either the ABC/3TC
+ ATV (n= 210) or ABC/3TC + ATV/r (n = 209) treatment
groups. Of these, 90% (379/419) completed 84 weeks of
treatment. Three hundred and sixty-nine subjects (189 in the
unboosted ATV group and 180 in the ATV/r group) partici-
pated in the extension phase (five subjects from each group
did not reconsent for this study phase). Eighty-five percent
(160/189) of the unboosted ATV group and 86% (154/180)
of the ATV/r group completed 144 weeks of antiretroviral
therapy.
Baseline characteristics of the extension population
(Table 1) were comparable to those of the subjects who en-
tered ARIES.25 The characteristics of the ATV/r and ATV
groups were similar, with the exception of a significantly
greater proportion of subjects with CDC classification C in
the unboosted ATV group (17% vs. 8%, p= 0.0184) and a
greater proportion of subjects with a baseline CD4 + count
< 50 cells/mm3 in the unboosted ATV group (17% vs. 10%;
p = 0.0672). The majority of the study subjects were male
(85%), with a median baseline HIV-1 RNA of 5.06 log10 cop-
ies/ml and similar median baseline CD4 + cell count of 198
cells/mm3. Fifty-six percent of study subjects entered the
study with viral loads ‡ 100,000 copies/ml.
Framingham 10-year risk score changes
At baseline, most of the subjects (83% in the unboosted
ATV group, 82% in the ATV/r group) had a low ( < 6%) risk of
having an MI within 10 years, as calculated by the Framing-
ham equation, and the remainder had risk scores of ‡ 6%
(Table 1). In the ATV group, 7% (11/153) at < 6% risk at
baseline were reclassified to ‡ 6% risk by week 144, while 5%
(7/153) at ‡ 6% risk at baseline were reclassified to < 6% risk
by week 144. Conversely, in the ATV/r group, 9% (13/146) of
subjects at < 6% risk at baseline were reclassified to ‡ 6% risk
by week 144, while 3% (5/146) at ‡ 6% risk at baseline were
reclassified to < 6% risk by week 144.
Within each treatment regimen, median Framingham 10-
year risk scores showed little change inmedian risk over time.
The unboosted ATV group had a median [interquartile range
(IQR), Q1–Q3] Framingham 10-year risk score of 1% (0–20%)
at baseline, 1% (0–25%) at week 84, and 1% (0–31%) at week
144, while the ATV/r group had amedian (IQR) Framingham
10-year risk score of 1% (0–20%) at baseline, 2% (0–31%) at
week 84, and 2% (0–31%) at week 144.
In a subsequent analysis by gender, Framingham 10-year
risk scores also showed little change over time. For the
unboosted ATV group, females had median (IQR, Q1–Q3)
Framingham 10-year scores of 0% (0–14%) at baseline, 0%
(0–11%) at week 84, and 1% (0–6%) at week 144, and males
had scores of 1% (0–20%) at baseline, 1% (0–25%) at week 84,
and 1% (0–31%) at week 144. Similarly, in the ATV/r group,
the scores in females were 0% (0–11%) at baseline, 0% (0–8%)
at week 84, and 0% (0–11%) at week 144, and the scores in
males were 2% (0–20%) at baseline, 2% (0–31%) at week 84,
and 3% (0–31%) at week 144.
Biomarker changes in the overall population
For the overall population, biomarker changes between the
start of treatment and 144 weeks were minimal (Table 2).
Median hsCRP concentrations in subjects with baseline Fra-
mingham risk scores < 6% did not differ significantly between
baseline (1.6mg/liter) and week 84 (1.6mg/liter; p = 0.677) or
between baseline and week 144 (1.4mg/liter; p= 0.535).
Similarly, for subjects with baseline Framingham risk scores
‡ 6%, median hsCRP concentrations did not differ significantly
between baseline (1.9mg/liter) and week 84 (1.7mg/liter;
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p = 0.589) or between baseline and week 144 (2.0mg/liter;
p = 0.102).
In the IL-6 analyses, median concentrations in subjects with
baseline Framingham risk scores < 6% (1.6 pg/ml) declined
significantly ( p< 0.001) at week 84 to 1.2 pg/ml, and re-
mained marginally lower than the baseline value at week 144
(1.4 pg/ml), although this difference was not statistically
significant ( p= 0.267). In subjects with baseline risk scores
‡ 6%, median values remained relatively stable between
baseline and week 84 (from 2.0 to 1.8 pg/ml, p = 0.522) before
slightly increasing to a level that was nonsignificantly higher
than baseline at week 144 (2.2 pg/ml, p = 0.099).
Of the biomarkers, the most consistent reduction in con-
centrations over the entire 144-week study period occurred in
Lp-PLA2 activity. Thus, in subjects with baseline Framingham
CHD risk scores < 6%, median Lp-PLA2 activity fell signifi-
cantly from a baseline of 197 to 189 nmol/min/ml at week 84
( p < 0.001) and to 168 nmol/min/ml at week 144 ( p< 0.001).
Similarly, in subjects with baseline risk scores ‡ 6%, median
Lp-PLA2 activity decreased significantly from a baseline of
238 to 210 nmol/min/ml at week 84 ( p < 0.001) and to
175 nmol/min/ml at week 144 ( p< 0.001).
Biomarker changes by treatment group
Since levels of hsCRP > 3mg/liter have been considered by
some groups to be a critical clinical cut-off for patients at ‘‘high
risk’’ for future heart disease, the hsCRP biomarker results
were evaluated by treatment group applying this cut-point. In
the ATV/r-treated group for subjects with paired baseline
and week 144 data, the proportion of subjects with hsCRP
> 3mg/liter at baseline was 30% (45/152 subjects) and re-
mained similar to that observed at week 144 [34% (51/152
subjects)]. Likewise, in the unboosted ATV-treated group, the
Table 1. Intent-to-Treat Extension Phase Patient Demographics
ATV + ABC/3TC ATV/r + ABC/3TC Total
Median (range) or % N = 189 N= 180 N = 369
Male sex 85% 86% 85%
Age, years (range) 36 (19–72) 39 (20–67) 38 (19–72)
Racial distribution
White 122 (65%) 114 (63%) 236 (64%)
Black 58 (31%) 57 (32%) 115 (31%)
Other 9 (5%) 9 (5%) 18 (5%)
Median HIV-1 RNA, log10 copies/ml 5.06 5.08 5.06
< 100,000 85 (45%) 79 (44%) 164 (44%)
‡ 100,000 104 (55%) 101 (56%) 205 (56%)
Median CD4 + count, cells/mm3 190 203 198
‡ 200 91 (48%) 92 (51%) 183 (50%)
50–< 200 66 (35%) 70 (39%) 136 (37%)
< 50 32 (17%) 18 (10%) 50 (14%)
CDC Class C 17% 8% 13%
Hepatitis C positive 5% 6% 5%
Blood pressure, mm Hg (range)a
Diastolic 79 (54–103) 78 (57–99) 78 (54–103)
Systolic 121 (90–185) 124 (100–190) 122 (90–190)
Smokersb 38% 39% 38%
Weight (kg) 75.5 (46.4–144.7) 75.4 (47.6–155.5) 75.5 (46.4–155.5)
Diabetes (Type I and II)c 5% 6% 5%
Fasting lipids, mg/dl (range)
Total cholesterol 152 (70–287) 153 (52–256) 152 (52–287)
LDL-cholesterol 88 (15–216) 85 (3–188) 86 (3–216)
HDL-cholesterol 37 (13–74) 39 (3–79) 38 (3–79)
Triglycerides 127 (49–798) 123 (49–417) 124 (43–798)
Framingham risk score, n (%)
< 6% (low risk) 148 (83%) 140 (82%) 288 (82%)
‡ 6% (higher risk) 31 (17%) 30 (18%) 61 (18%)
Creatinine clearance (C-G), ml/min 113 (55–271) 107 (56–222) 111 (55–271)
MDRD GFR, ml/min/1.73m2 92 (43–174) 89 (49–143) 90 (43–174)
aBlood pressure was assessed at weeks 84 and 144; week 144 results are shown.
bSmoking status was assessed at weeks 84 and 144; if the subject indicated at either visit that they smoked they were considered a smoker.
cDiabetes was assessed at baseline, week 84, and week 144; the subject was considered diabetic if they were assessed at such at any visit;
however, there was little or no increase over the course of the study.
CDC, Centers for Disease Control and Prevention; C-G, Cockcroft–Gault equation for calculating creatinine clearance; GFR, glomerular
filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDRD, modification of diet in renal disease; ATV/r, atazanavir/
ritonavir; ABC/3TC, abacavir/lamivudine.
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proportion of subjects with hsCRP > 3mg/liter at baseline
[28% (44/159)] was virtually unchanged compared with that
at week 144 [27% (43/159)].
Regardless of whether subjects in the ATV/r and un-
boosted ATV groups had baseline Framingham risk scores
< 6% or ‡ 6%, no significant changes were observed between
baseline and week 84 or between baseline and week 144
(Table 2). There was a small but not statistically significant
decline in median hsCRP levels from baseline through week
144 for both treatment groups and, similarly, there was no
statistically significant change from baseline for this bio-
marker when evaluated by Framingham risk score for either
treatment group over 144 weeks.
In the IL-6 analyses, subjects with Framingham risk scores
< 6% in the ATV/r and unboosted ATV groups had a signif-
icant decrease in median IL-6 concentrations at week 84
compared to baseline, which was no longer apparent at
week 144 (Table 2). No other significant changes from baseline
were observed at week 84 or week 144 in either treatment
group regardless of baseline Framingham risk score being
< 6% or ‡ 6%.
In the Lp-PLA2 analyses, the ATV/r and unboosted ATV
groups had significant decreases from baseline in Lp-PLA2
concentrations at both week 84 and week 144, and this was
observed in subjects with baseline Framingham risk scores
< 6% as well as those with scores ‡ 6% (Table 2).
Table 2. Biomarker Data
Study visit
Baseline Week 84 Week 144
10-Year Framingham CHD risk score n Median (Q1–Q3) n Median (Q1–Q3) p-valuea n Median (Q1–Q3) p-valuea
hsCRP (mg/liter)
ATV and ATV/r arms combined
< 6% 285 1.6 (0.6–3.4) 280 1.6 (0.6–2.9) 0.677 249 1.4 (0.6–3.4) 0.535
‡ 6% 61 1.9 (0.9–2.8) 60 1.7 (0.8–4.9) 0.589 50 2.0 (1.2–5.0) 0.102
All 346 1.6 (0.7–3.3) 340 1.6 (0.6–3.3) 0.901 299 1.5 (0.6–3.7) 0.949
ATV arm alone
< 6% 147 1.5 (0.6–3.5) 144 1.6 (0.7–3.4) 0.460 128 1.2 (0.6–2.6) 0.636
‡ 6% 31 1.8 (0.7–3.6) 30 1.5 (0.8–3.5) 0.480 25 1.9 (0.8–5.3) 0.076
All 178 1.6 (0.6–3.5) 174 1.6 (0.7–3.5) 0.620 153 1.3 (0.6–3.4) 0.825
ATV/r arm alone
< 6% 138 1.6 (0.6–3.4) 136 1.4 (0.5–2.7) 0.164 121 1.5 (0.6–3.7) 0.669
‡ 6% 30 2.0 (1.0–2.7) 30 2.1 (0.7–6.5) 0.176 25 2.0 (1.3–4.4) 0.607
All 168 1.6 (0.7–3.1) 166 1.6 (0.6–3.1) 0.502 146 1.5 (0.7–4.0) 0.866
IL-6 (pg/ml)
ATV and ATV/r arms combined
< 6% 287 1.6 (1.0–2.5) 287 1.2 (0.8–2.0) < 0.001 249 1.4 (0.9–2.3) 0.267
‡ 6% 61 2.0 (1.3–2.6) 61 1.8 (1.2–2.7) 0.522 50 2.2 (1.5–3.5) 0.099
All 348 1.6 (1.0–2.5) 348 1.3 (0.8–2.1) < 0.001 299 1.5 (1.0–2.6) 0.846
ATV arm alone
< 6% 147 1.6 (1.0–2.6) 147 1.2 (0.8–2.2) 0.003 128 1.4 (0.9–2.4) 0.442
‡ 6% 31 1.9 (1.1–3.1) 31 1.5 (1.1–2.1) 0.422 25 1.9 (1.4–3.4) 0.638
All 178 1.6 (1.0–2.6) 178 1.3 (0.8–2.2) 0.003 153 1.5 (1.0–2.4) 0.596
ATV/r arm alone
< 6% 140 1.5 (1.0–2.4) 140 1.2 (0.8–2.0) < 0.001 121 1.3 (0.8–2.3) 0.420
‡ 6% 30 2.1 (1.4–2.6) 30 2.2 (1.2–2.9) 0.897 25 2.4 (1.8–4.2) 0.065
All 170 1.6 (1.1–2.5) 170 1.3 (0.9–2.1) 0.002 146 1.5 (1.0–2.8) 0.809
Lp-PLA2 (nmol/min/ml)
ATV and ATV/r arms combined
< 6% 284 197 (162–238) 287 189 (150–217) < 0.001 249 168 (138–198) < 0.001
‡ 6% 60 238 (202–278) 61 210 (176–238) < 0.001 50 175 (147–213) < 0.001
All 344 203 (166–250) 348 191 (153–220) < 0.001 299 171 (138–199) < 0.001
ATV arm alone
< 6% 146 193 (159–224) 147 180 (147–211) < 0.001 128 165 (138–197) < 0.001
‡ 6% 30 238 (206–285) 31 211 (177–246) 0.010 25 172 (149–199) < 0.001
All 176 197 (160–237) 178 185 (154–217) < 0.001 153 165 (139–198) < 0.001
ATV/r arm alone
< 6% 138 208 (170–253) 140 195 (151–221) < 0.001 121 169 (137–199) < 0.001
‡ 6% 30 237 (198–277) 30 202 (169–238) < 0.001 25 175 (147–216) < 0.001
All 168 212 (174–255) 170 195 (152–225) < 0.001 146 172 (137–206) < 0.001
ap-values from Wilcoxon signed-rank test comparing baseline and postbaseline.
CHD, coronary heart disease; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; Lp-PLA2, lipoprotein-associated phospho-
lipase A2; Q1–Q3, first quartile through third quartile; ATV/r, atazanavir/ritonavir.
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Lipid changes
At baseline, the ATV/r and ATV groups were similar
with respect to median total cholesterol (153 vs. 152mg/dl),
LDL-cholesterol (85 vs. 88mg/dl), HDL-cholesterol (39 vs.
37mg/dl), total cholesterol/HDL-cholesterol ratio (4.10 vs.
4.15), and triglycerides (123 vs. 127mg/dl) (Table 3). At week
144, the ATV/r treatment group had a significantly greater
increase than the unboosted ATV treatment group in total
cholesterol ( p= 0.003) and LDL-cholesterol ( p= 0.05), a sig-
nificantly higher triglyceride concentration ( p < 0.001) and
lower total cholesterol/HDL-cholesterol ratio ( p= 0.017), and
a similar increase in HDL-cholesterol ( p = 0.952). Week 144
median fasting total and LDL-cholesterol levels remained
below NCEP cut-points in both groups. The median fasting
triglyceride level remained below the NCEP cut-point in the
ATV group but not the ATV/r group.
Discussion
The majority of subjects in ARIES had Framingham risk
scores of < 6% at baseline, suggesting they were at relatively
low cardiovascular risk. Median Framingham risk scores did
not change significantly over 144 weeks, which is consistent
with the results of two shorter term studies (Bicombo-met and
STEAL).30,31 In these studies, when an ABC/3TC nucleoside
backbone was compared to another nucleoside/nucleotide
backbone, tenofovir/emtricitabine (TDF/FTC), no significant
changes in median or mean Framingham 10-year CHD risk
scores over 48 and 96 weeks were observed.
Since changes in hsCRP concentrations have been previ-
ously shown to mirror changes in Framingham risk scores in
non-HIV-infected populations, it was hypothesized that this
would also be observed in HIV-infected subjects.32 There was
no significant change between baseline and week 144 in
median hsCRP and IL-6 levels in the overall study population,
or by risk group (< 6% or ‡ 6%)within the overall population.
Similarly, in other studies a lack of significant long-term
effect of ABC/3TC on these biomarkers has been shown in
antiretroviral-experienced subjects who have been switched
from non-ABC-containing regimens to ABC/3TC regimens,
although these studies involved smaller populations and a
shorter period (typically 12 months) of observation.33–35 With
respect to the hsCRP findings in our study, no change was
seen over 144 weeks in the proportion of subjects with hsCRP
> 3mg/liter, considered by the American Heart Association
and Centers for Disease Control and Prevention to be a critical
clinical cut-off point for patients at ‘‘high risk’’ for future heart
disease (including MI and stroke) and an increased mortality
rate.36,37
Lp-PLA2 has been reported to be a better predictor of risk of
coronary events than hsCRP because, unlike hsCRP, its pre-
dictability is not attenuatedwhen age, systolic blood pressure,
and lipoprotein levels are included in multivariate models of
analysis.38 Reductions in Lp-PLA2 have been hypothesized to
correlate with reduction in the atherosclerotic process.39 In
our study we found that in contrast to hsCRP and IL-6,
median Lp-PLA2 activity decreased significantly and consis-
tently over the 144-week course of the study in both < 6% and
‡ 6% Framingham CHD risk-score groups. The effect of ABC
on Lp-PLA2 has been evaluated previously over a shorter
period (48 weeks) in another study, but did not change sig-
nificantly in that time frame.30 Our study is the first to report
Lp-PLA2 data with an unboosted ATV or ATV/r regimen.
Since it is known that low doses of ritonavir, in the ab-
sence of coadministered antiretroviral drugs, can produce
elevations in lipids within 2 weeks,15 the relatively greater
elevation in fasting total cholesterol, LDL-cholesterol, and
triglycerides seen in subjects who remained on the ritonavir-
boosted ATV regimen compared to the unboosted ATV reg-
imen was not unexpected. Similar findings also have been
reported in other studies comparing the use of ritonavir in
regimens containing ABC/3TC and ATV in antiretroviral-
naive patients.40,41 Despite the elevations in these particular
lipids for subjects receiving the ritonavir-boosted regimen, it
should be noted that median values for the ATV/r-treated
subjects remained below NCEP cutoffs for use of lipid-
lowering agents. Among the ritonavir-boosted protease in-
hibitors, ATV/r has low lipogenicity, as evidenced by fewer
lipid increases than lopinavir/r and only small lipid eleva-
tions reported in direct comparisons in treatment-naive sub-
jects14,42 and in treatment-experienced subjects switched from
lopinavir/r to ATV/r.43,44 Unboosted ATV, relative to most
other protease inhibitors, has been documented to have little
effect on lipids,45 which is consistent with what we observed.
The median 15-mg/dl increase in HDL-cholesterol seen in
Table 3. Change in Fasting Lipids
BL ATV,
ATV/r
Change from
BL to week 36
ATV, ATV/r
Change from
week 36 to week
144 ATV, ATV/r
Change from BL
to week 144
ATV, ATV/r
Total cholesterol, mg/dl (median) 152, 153 + 31, + 30 - 10, + 3 + 18, + 37.5
p-value 0.7626 0.4138 0.005 0.0031
HDL-cholesterol, mg/dl (median) 37, 39 + 10, + 8 + 3, + 3 + 12, + 12
p-value 0.8641 0.7269 0.8492 0.9515
LDL-cholesterol, mg/dl (median) 88, 85 + 13, + 10 - 4, 0 + 4, + 15
p-value 0.9662 0.2490 0.1195 0.05
Total cholesterol/HDL-cholesterol ratio (median) 4.15, 4.10 - 0.14, - 0.14 - 0.43, - 0.19 - 0.55, - 0.23
p-value 0.9207 0.3532 0.0076 0.0168
Triglyceride, mg/dl (median) 127, 123 + 27, + 34 - 42, - 11 - 8.5, + 28.5
p-value 0.7550 0.7005 < 0.0001 0.0001
p-values from Wilcoxon rank-sum test comparing ATV and ATV/r groups.
ATV, atazanavir; ATV/r, atazanavir/ritonavir; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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both the unboosted ATV and ATV/r groups allowed the total
cholesterol/HDL-cholesterol ratio to improve slightly.
In our biomarker analysis, we were also able to stratify the
change in median biomarker levels over 144 weeks by treat-
ment group. There was no significant change between base-
line andweek 144 inmedian hsCRP and IL-6 levels in the ATV
or ATV/r treatment groups, or within each treatment group
when stratified by the Framingham CHD risk group (< 6% or
‡ 6%). As was seen for the overall population, the median Lp-
PLA2 activity decreased significantly and consistently over
the 144-week course of the study in both treatment groups
and when stratified within treatment groups into < 6% and
‡ 6% Framingham risk groups. In ARIES, subjects with low
baseline CV risk demonstrated no increase in CV risk over
time and no significant increase in CV-associated biomarker
levels. No MIs were observed during the 144 weeks of the
ARIES study.27 In our study, we observed no significant
change in Framingham 10-year CHD risk scores, hsCRP,
and IL-6 concentrations, declines in Lp-PLA2 activity (hy-
pothesized to correlate with reductions in the atherosclerotic
process38), and improvements in the total cholesterol/HDL-
cholesterol ratio over 144 weeks with ABC/3TC + ATV-
containing regimens. These results are consistent with those
from many studies that have evaluated ABC-containing reg-
imens and failed to observe an increase in estimated cardiac
risk,18–22,46 and contrast with findings from two recent
observational cohorts analyses that reported a statistically
increased incidence in MI in HIV-infected patients receiving
ABC-based therapy with various third agents.23,24 For our
study, as with other studies, confounding risk factors such as
recreational drug use or alcohol consumption may impact the
findings but may be difficult to assess. Our prospective study
examined only ART-naive subjects who had low cardiovas-
cular risk, while in observational studies (where most subjects
are treatment-experienced), selection and classification bias,
in addition to confounding risk factors, can be more
pronounced than that within a rigorous clinical study. No
randomized clinical studies conducted to date have demon-
strated a clear association with any type of antiretroviral
therapy and CHD endpoints.47
This study focused on three cardiovascular biomarkers that
previously have been associated with cardiovascular disease
risk. Several other studies have examined additional bio-
markers, including D-dimer, tumor necrosis factor (TNF)-a,
soluble intercellular adhesion molecule-1, soluble vascular
adhesion molecule-1, selectin E, selectin P, adiponectin,
myeloperoxidase, amyloid A, and amyloid P, and generally
showed no significant changes inmedian ormean values over
at least 48 weeks of continuous ABC use.19,34,35
In conclusion, the majority of antiretroviral-naive subjects
(81%) in this study had relatively low baseline cardiovascular
risk. After initiating treatment with ABC/3TC plus ATV/r
and then randomizing at week 36 to remain on ATV/r or
simplify to unboosted ATV for an additional 108 weeks,
cardiovascular risk status, as estimated by Framingham
risk score categories ( < 6% and ‡ 6%), remained relatively
stable over this period, with improvement in median HDL-
cholesterol levels for both ATV- and ATV/r-treated subjects.
Over 144 weeks, median biomarker levels remained stable or
declined overall, with significant declines observed for Lp-
PLA2 irrespective of whether ritonavir was maintained or
discontinued after 36 weeks.
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